ZYKADIA Drug Patent Profile

When do Zykadia patents expire, and what generic alternatives are available?

Zykadia is a drug marketed by Novartis and is included in two NDAs. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ceritinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Zykadia

Zykadia was eligible for patent challenges on April 29, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 29, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZYKADIA

International Patents:	322
US Patents:	8
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for ZYKADIA

ZYKADIA is protected by eight US patents.

This potential generic entry date is based on patent 8,039,479.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No	8,377,921
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No	7,964,592		Y	Y
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No	8,399,450		Y	Y
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes	8,039,479		Y	Y
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes	8,703,787
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes	7,964,592		Y	Y

International Patents for ZYKADIA

When does loss-of-exclusivity occur for ZYKADIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

France

Georgia, Republic of

Guatemala

Honduras

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Poland

Portugal

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZYKADIA around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P20130724
Japan	4658477
Argentina	107965	DERIVADOS DE PIRIMIDINA
Poland	1833791
Taiwan	201033588
Australia	2008296545

Supplementary Protection Certificates for ZYKADIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2091918	92785	Luxembourg		PRODUCT NAME: CERITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20150508
2091918	528	Finland
1272477	SPC/GB15/057	United Kingdom		PRODUCT NAME: CERITINIB, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/15/999 20150508
2091918	15C0058	France		PRODUCT NAME: CERITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/999 20150508
1272477	15C0064	France		PRODUCT NAME: CERITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/15/999 20150508
1272477	1590048-3	Sweden		PRODUCT NAME: CERITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/999 20150508

ZYKADIA (ceritinib) Investment Scenario and Fundamentals Analysis

Last updated: April 25, 2026

What is ZYKADIA and how does it make money?

ZYKADIA is ceritinib, an oral next-generation ALK inhibitor developed for ALK-positive metastatic non-small cell lung cancer (NSCLC). In marketed form, it is positioned as a line-of-therapy option in ALK-driven disease where the clinical differentiation historically came from activity after progression on earlier ALK inhibitors and overall response durability in ALK-positive populations.

Core commercialization anchors (market-facing):

• Indication focus: ALK-positive metastatic NSCLC (adult).
• Dosing form: oral tablets (brand platform; generics not applicable to “brand-only” analysis once patent/market exclusivity erodes in a given geography).
• Commercial model: brand pricing until exclusivity erosion, then erosion via generics/biosimilars substitutes is typically the principal driver of long-term revenue pressure for small-molecule brands.

What is the patent and exclusivity posture that matters for investors?

A complete, geography-level patent landscape is required to time exclusivity transitions, generics entry probability, and value at risk. This response provides no such dataset. It therefore cannot produce a defensible investment view tied to litigation milestones, expiration dates, or country-by-country exclusivity.

What do the fundamentals say about clinical positioning?

Ceritinib’s investment relevance depends on where it sits in the ALK-treatment algorithm and whether it retains share in real-world sequencing.

Practical clinical positioning tests investors use:

• Line-of-therapy retention: whether ceritinib is still used after more recent ALK inhibitors consolidate first-line share.
• Switching behavior: how often patients move between ALK agents after progression.
• Constraint by tolerability and dosing convenience: once newer agents with better tolerability and dosing emerge, older TKIs tend to lose share even if efficacy is still present.

Investment implication: Without current prescribing-share or real-world utilization data by line and geography, the only defensible “fundamentals” analysis is structural: ceritinib is a legacy ALK TKI in a category that has steadily migrated to newer, more convenient regimens. That typically translates into secular revenue compression absent new label expansion or differentiated patient subgroups that sustain uptake.

What are the key market fundamentals for a legacy ALK TKI brand?

For ZYKADIA specifically, investors generally underwrite these drivers:

1) Category competition and sequencing

• ALK inhibitor competition is intense and evolves quickly with approvals for newer agents.
• In ALK NSCLC, treatment algorithms frequently shift toward agents that combine first-line or broad efficacy with improved tolerability profiles and dosing simplicity.

2) Loss of exclusivity and channel price compression

• Once exclusivity ends, small molecules commonly face rapid price pressure from generics and negotiated channel discounts.
• For legacy oncology brands, gross-to-net dilution accelerates with discounting to preserve share.

3) Geographic mix

• Adoption patterns differ by country reimbursement logic and formulary inclusion.
• Investors typically track whether a brand maintains share in high-reimbursement markets after competitive entries.

4) Portfolio spillover from the manufacturer

• If the company’s current growth depends on a different pipeline asset, a legacy revenue base tends to be treated as cash-flow support, not a growth engine.
• That influences R&D allocation and marketing spend, which in turn affects continued brand competitiveness.

What does an “investment scenario” look like for ZYKADIA (base case mechanics)?

This section models the direction of change, not a precise valuation, because the required inputs (revenue history, margins, forecast, country breakdown, and exclusivity dates) are not provided in the available materials.

Base case (typical legacy TKI outcome)

• Revenue trend: gradual decline as competition and switching reduce market share.
• Gross margin: compresses over time from discounting and post-exclusivity price erosion.
• Net sales volatility: tied to formulary status and competitive availability rather than new uptake.
• Cash flow: remains positive short-to-medium term if exclusivity still holds in key markets, then declines when generics pressure deepens.

Bear case

• Faster-than-expected displacement in key lines due to payer preference toward newer ALK TKIs.
• Earlier loss of pricing power and steeper net sales decline.
• Higher SG&A relative to sales for defense marketing and contract renegotiation.

Bull case

• Sustained differentiation in a specific subgroup or sequencing niche where ceritinib remains preferred.
• Slower exclusivity erosion in key geographies.
• Better-than-expected payer retention through contract depth and inventory planning.

What to underwrite specifically before investing

To do a decision-grade underwriting, investors usually build a “Zykadia fundamentals dashboard” on these measurable inputs:

Fundamentals component	What it must confirm	What success looks like
Uptake and share by line	Remaining use in first-line and post-progression	Stable or slowly declining share with limited displacement
Real-world persistence	Time on treatment after initiation	Longer persistence than competing agents
Pricing power	Gross-to-net and average selling price trend	Net sales hold up despite competitive entry
Exclusivity timing by geography	Patent and data exclusivity end dates	Predictable transition with planned mitigation
Competitive environment	Market entries that affect formulary preference	No major late entrants that displace ceritinib faster than expected

This analysis is action-oriented, but without the missing datasets, it cannot set a probability-weighted outcome or provide a valuation bridge.

Investment risk map (what can break the thesis)

Regulatory and competitive risks

• Label changes that shift treatment toward newer ALK inhibitors.
• New comparative evidence that makes clinicians and payers move away from ceritinib.

Commercial execution risks

• Formulary exclusions or restrictive prior authorization that increases friction.
• Contract loss to competing TKIs with stronger rebate terms.

IP and supply risks

• Earlier-than-expected generic entry in a material market.
• Enforcement outcomes that accelerate loss of exclusivity.

What are the business takeaways for capital allocation?

• ZYKADIA is a legacy ALK franchise product. The fundamental investment question is not whether ceritinib works, but whether it retains pricing power and share long enough to justify holding exposure versus deploying capital into newer ALK agents or broader oncology growth engines.
• The most decisive swing factors for a legacy oncology brand investment are: 1) real-world utilization and persistence,
  2) gross-to-net dilution and formulary retention,
  3) exact exclusivity end timing across your target geographies.

Key Takeaways

• ZYKADIA (ceritinib) is a legacy oral ALK TKI in metastatic ALK-positive NSCLC, so investment returns depend primarily on share maintenance, pricing power, and exclusivity timing, not on new growth curves.
• In ALK NSCLC, competitive sequencing typically erodes older TKIs unless ceritinib retains a distinct payer or clinician niche.
• A decision-grade investment view requires market-share-by-line, pricing (gross-to-net), and country-specific IP and exclusivity timing. Without those inputs, only directional scenario framing is defensible.
• Risk is concentrated in formulary displacement and exclusivity/generic transition in key markets.

FAQs

1) Is ZYKADIA still competitive in ALK-positive metastatic NSCLC?
It is evaluated in the context of newer ALK inhibitors. Competitive displacement risk is structurally high for older ALK TKIs as treatment algorithms shift.

2) What are the biggest drivers of ZYKADIA revenue in later life-cycle stages?
Pricing power (gross-to-net), formulary access, and line-of-therapy sequencing in real-world practice.

3) How does exclusivity affect investment timing for ZYKADIA?
Exclusivity determines the pace of generic entry risk and the duration of price protection in each geography, which is a dominant driver of revenue trajectories for small-molecule brands.

4) What commercial indicators matter most for ongoing ZYKADIA sales?
Net sales stability versus gross-to-net deterioration, persistence rates, and formulary/contract retention.

5) What type of thesis is most appropriate for ZYKADIA?
A cash-flow and downside-management thesis tied to market share retention and exclusivity runway, rather than a high-growth thesis.

References

[1] FDA. ZYKADIA (ceritinib) prescribing information. U.S. Food and Drug Administration. (Referenced for product/label context).